Abstract: Presented herein are methods and compositions for treating congenital diarrheal disorders (CDD). Methods comprise administering to a patient in need thereof, an effective amount of a proanthocyanidin polymer composition from C. lechleri, preferably crofelemer. Administration of the proanthocyanidin polymer composition addresses the secretory diarrhea and symptoms associated therewith caused by the CDD and can improve nutritional status, electrolyte balance, hydration, growth and development of the patient.

Abstract: Presented herein are methods for treating bile acid diarrhea, short bowel syndrome (SBS), and cholecystectomy-associated diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. In particular embodiments, infants, and juveniles with SBS are treated with an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.

Abstract: Presented herein are methods for treating bile acid diarrhea, short bowel syndrome (SBS), and cholecystectomy-associated diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. In particular embodiments, infants, and juveniles with SBS are treated with an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.

Abstract: Presented herein are methods and compositions for treating congenital diarrheal disorders (CDD). Methods comprise administering to a patient in need thereof, an effective amount of a proanthocyanidin polymer composition from C. lechleri, preferably crofelemer. Administration of the proanthocyanidin polymer composition addresses the secretory diarrhea and symptoms associated therewith caused by the CDD and can improve nutritional status, electrolyte balance, hydration, growth and development of the patient.

Abstract: The invention provides for compositions for treating a cancer or an inflammatory disorder comprising a combination of agents in a pharmaceutically acceptable carrier, wherein said agents comprise: (i) a non-covalent DNA binding agent; and (ii) an anti-cancer or anti-inflammatory agent.

Abstract: The invention provides for compositions for treating a cancer or an inflammatory disorder comprising a combination of agents in a pharmaceutically acceptable carrier, wherein said agents comprise: (i) a non-covalent DNA binding agent; and (ii) an anti-cancer or anti-inflammatory agent.

Abstract: The present invention relates generally to compositions and methods for oral delivery of nordihydroguaiaretic acid (NDGA). More particularly, the present invention relates to pharmacologically optimized multimodal drug delivery systems for orally administered NDGA and methods for preparation and use thereof.

Abstract: The present invention relates generally to compositions and methods for oral delivery of nordihydroguaiaretic acid (NDGA). More particularly, the present invention relates to pharmacologically optimized multimodal drug delivery systems for orally administered NDGA and methods for preparation and use thereof.

Abstract: The invention provides for compositions for treating a cancer or an inflammatory disorder comprising a combination of agents in a pharmaceutically acceptable carrier, wherein said agents comprise: (i) a non-covalent DNA binding agent; and (ii) an anti-cancer or anti-inflammatory agent.

Abstract: The present invention relates generally to compositions and methods for oral delivery of nordihydroguaiaretic acid (NDGA). More particularly, the present invention relates to pharmacologically optimized multimodal drug delivery systems for orally administered NDGA and methods for preparation and use thereof.

Abstract: The present invention relates generally to compositions and methods for oral delivery of nordihydroguaiaretic acid (NDGA). More particularly, the present invention relates to pharmacologically optimized multimodal drug delivery systems for orally administered NDGA and methods for preparation and use thereof.

Abstract: The present invention relates to the use of butyrate esters of threitol, alone or in combination with other agents, in pharmaceutical compositions and methods for increasing fetal hemoglobin and gamma globin in a patient. These methods are particularly useful in treating .beta.-hemoglobinopathies, such as sickle cell syndromes and .beta.-thalassemia syndromes. Compositions comprising butyrate esters of threitol, alone or in combination antiproliferative and differentiating agents are also useful in methods for inducing cell differentiation in malignant cells. These methods are useful in treating cancer, particularly the tetrabutyrate ester.

Abstract: The present invention relates to the use of butyrate esters of threitol, alone or in combination with other agents, in pharmaceutical compositions and methods for increasing fetal hemoglobin and gamma globin in a patient. These methods are particularly useful in treating .beta.-hemoglobinopathies, such as sickle cell syndromes and .beta.-thalassemia syndromes. Compositions comprising butyrate esters of threitol, alone or in combination antiproliferative and differentiating agents are also useful in methods for inducing cell differentiation in malignant cells. These methods are useful in treating cancer, particularly the tetrabutyrate ester.